Remdesivir is approved for testing on coronavirus patients in Brazil and Europe

Brazil can already start testing with remdesivir, an antiviral medication, in the treatment of patients with COVID-19, according to a statement made by the Brazilian Health Regulatory Agency (Anvisa) on Wednesday (25).

Anvisa also announced that the study to be carried out in the country will be phase 3, which involves the observation of patients who are being treated with the drug. People who are already hospitalized with severe pneumonia caused by the new coronavirus will receive the drug, divided into two groups.

The first will be treated with remdesivir combined with another medication called tocilizumab, which acts in the body as an immunoregulator and is used against rheumatoid arthritis. The second group will receive remdesivir given with a placebo. The idea is that in Brazil, according to authorization requested by the company PPD do Brasil Suporte a Pesquisa Clínica Ltda, 105 patients pass the test.

Approval in Europe

Remdesivir has also received approval from the European Medicines Agency (EMA), which can now be prescribed for patients diagnosed with COVID-19, requiring mechanical breathing, and who are 12 years of age or older. It is up to the European Commission to finalize the authorization in a bureaucratic manner, which should happen within a week. Once approved, the indication of the drug will be in force in 27 countries and will be valid for one year.

As there is still no proof that the drug is really effective against COVID-19, the North American pharmaceutical manufacturer Gilead needs to inform the European Union of the results of the remdesivir tests, as well as their side effects, by December.

What is Remdesivir for?

Remdesivir is an antiviral developed to combat Ebola, but which has already shown positive results in the treatment of other types of coronavirus, responsible for SARS and MERS diseases. In the United States, the drug has already been approved for serious patients in COVID-19, shortly after authorization by the regulatory agency Food and Drug Administration (FDA).

According to the FDA, the criterion used to approve the drug was a study by the American National Institute of Health (NIH), which conducted tests on 1,063 patients not only in the United States, but in Asia and Europe. The result showed that people treated with remdesivir recovered about four days before those who did not receive the drug. In early June, South Korea and India also began testing the drug.

News from: Canal Tech

rio de janeiro

Madrid Protocol and Brazilian culture

The accession of Brazil to the Madrid Protocol, in October 2019, brought not only a new way of protecting trademarks for Brazilian businessmen abroad, but also significant changes for those professionals working in the area of trademarks as well as challenges. One of these challenges is the translation of the names of various ingredients from the cuisine, drinks, typical dishes, musical instruments, and artistic expressions into English or Spanish, languages adopted by Brazil for the use of the Madrid Protocol. Not infrequently, what is expressed in the source language in a single term needs to be translated into a sentence in order to be understood.

Typical Brazilian products and services are included in the WIPO classifier

A beautiful initiative by members of the Brazilian Patent Office’s (BPTO) Products and Services Classification Commission (CCPS), together with the World Intellectual Property Organization (WIPO), resulted in the formulation of a robust list of typically Brazilian products and services and their inclusion in the classification nomenclatures of this entity, in the so-called Madrid Goods and Services Manager (MGS), with the respective translation. There are 668 descriptions of the most varied fruits, dishes, drinks, and services typically Brazilian.

According to information on the BPTO’s own website, the elaboration of this list aims to prevent offices in other countries from granting protection as a trademark for designations that are actually descriptive of the product or service itself. This study took into account the fact that not only Brazilian legislation, but also that of the vast majority of countries prohibit registration as a trademark of descriptive and/or generic terms in relation to the products or services of interest.

In addition, it is necessary to pay attention to the principle of the veracity of trademark preaches. By virtue of this principle, a trademark cannot be misleading, that is, it cannot mislead the consumer or in an improper association as to origin, composition, place of production, among other factors.

The compilation of these product and service descriptions and their inclusion in the Madrid Goods and Services Manager (MGS) with the English language equivalent can be considered an important milestone and a commendable effort, not only for the reasons already explained but also for corroborating aspects of our culture and tradition.

News from: ConJur


BPTO and CAS establish technical cooperation agreement to strengthen fight against patent backlog

According to a publication in the Official Gazette this Wednesday (06/10/2020), BPTO and CAS, a non-profit division of the American Chemical Society, signed a technical cooperation agreement to expedite the examination of patents. The agreement establishes BPTO’s participation in a CAS Search Report pilot, with the aim of improving the patent workflow at the Institute.

The technology, which will be tested and optimized, is able to assess similarities with the state of the art from parameters of a patent application important for the examiner’s analysis. In addition, the system combines machine learning and data selected by humans, which improves the results offered.

News from: BPTO